These findings demonstrated that XIST could serve as a potential prognostic biomarker in human cancers of gastric cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, pancreatic cancer, osteosarcoma, esophageal squamous cell carcinoma and cervical squamous cell carcinoma. This evidence concerns the gene XIST and familial pancreatic carcinoma.